Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation
NCT ID: NCT00895713
Last Updated: 2009-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
18 participants
INTERVENTIONAL
2004-11-30
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
NCT03519113
A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients
NCT02304315
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients
NCT01131065
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
NCT05686759
A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients
NCT01513850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
im HBIG Grifols
intramuscular hepatitis B virus immune globulin
Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intramuscular hepatitis B virus immune globulin
Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age \> 18 years and \< 70 years.
3. OLT recipient for HBV infection-related disease for \> 18 months before inclusion in the clinical trial.
4. Serum HBsAg-positive within 3 months before transplantation.
5. Serum HBsAg-negative just before inclusion in the clinical trial.
6. Serum HbeAg-negative just before inclusion in the clinical trial.
7. Serum HBV DNA-negative by DNA PCR-amplification assay (lower detection limit 102 genomes/ml) just before inclusion in the clinical trial.
8. Continuous and interrupted prophylaxis with HBIG after an-hepatic phase as part of the subject clinical care.
9. Trough serum HBsAg Ab (HBsAg IgG) titer (immediately pre-dose) \> 150 I.U./l in at least 2 consecutive determinations within last 3 months before inclusion in the clinical trail.
10. Signed informed consent.
Exclusion Criteria
2. Serum HBeAg-positive within 3 months before transplantation.
3. Serum HBV DNA-positive by standard DNA hybridisation assay (lower detection limit 105 genomes/ml), or by any less sensitivity technique, within 3 months before transplantation.
4. Unknown serum HBV replication status (no data about HbeAg and HBV DNA) within 3 months before transplantation.
5. Previous recurrence of HBV in the transplanted liver defined by serum HBV DNA- positive by sensitive hybridisation (lower detection limit 105 genomes/ml) assay or any less sensitive technique, and/or serum HBeAg-positive, and/or serum HBsAg-positive.
6. Re-transplanted liver even for reasons not related to HBV infection.
7. Evidence of hepatocellular carcinoma in the transplanted liver, or metastatic disease, at time of inclusion in the clinical trial.
8. Evidence of graft rejection at time of inclusion in the clinical trial.
9. Life-expectancy less than 1 year.
10. VHC infection.
11. HIV type 1 or type 2 infection.
12. Acute HAV infection.
13. Previous treatment with i.m. HBIG Grifols within 3 months before inclusion in the clinical trial.
14. Intolerance or allergy to any i.m. HBIG Grifols containing substance (glycine, sodium chloride, sterile water for injection, homologous human immune globulin).
15. History of SAEs related to the administration of human blood-derived products.
16. History of frequent AEs, even non-serious, related to the administration of human blood-derived products.
17. Selective IgA deficiency with Abs against IgA.
18. Platelet count \< 50 x 109/L.
19. Prothrombin time (PT) \< 60%.
20. Activated partial thromboplastin time (APTT) ratio \> 1.5.
21. Any haemostatic abnormality contraindicating i.m. injection according to investigator's judgement.
22. Haemoglobin \< 11 g/dl.
23. Alcohol or drug abuse at the moment or within 1 year before inclusion in the clinical trial.
24. Pregnant woman or woman who is expecting to be pregnant within 1 year after inclusion in the clinical trial.
25. Breast-feeding woman.
26. Any severe acute or chronic medical, surgical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, makes the subject inappropriate for entry in this clinical trial.
27. Impossibility to donate a serum sample before the first investigational product administration.
28. Planned treatment with Ig other than i.m. HBIG Grifols within the clinical trial period.
29. Planned modification, during the clinical trial period, of the prophylactic regimen with nucleoside analogues followed by the subjects, if any, within last 3 months before inclusion in the clinical trial.
30. The subject has been previously admitted to this clinical trial.
31. Participation in other clinical trial within 3 months before study inclusion.
32. Subject's incapacity of giving consent personally.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Grifols, S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Instituto Grifols S.A.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franco Filipponi, Prof. MD
Role: PRINCIPAL_INVESTIGATOR
Liver Transplantation Co-ordinating Section. Cisanello Hospital. (University of Pisa).
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cisanello Hospital. (University of Pisa).
Pisa, , Italy
Ospedaliera Molinette
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IG302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.